Please login to the form below

Not currently logged in

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

Johnson and Johnson logo Johnson & Johnson has acquired California-based clinical stage biopharma company Alios BioPharma for $1.75bn.

The deal will give it access to a portfolio of potential therapeutics for viral infections, including the orally administered AL-8176.

The antiviral therapy has the potential to be first-in-class and is currently in phase II studies as a treatment for respiratory syncytial virus (RSV) in infants.

William Hait, global head of research and development for Janssen Pharmaceutical Companies of Johnson & Johnson, said: “We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major paediatric diseases with no available preventive therapy.

“AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five,” he added.

The acquisition will include Alios BioPharma's preclinical programmes that target influenza and rhinovirus, as well as RSV.

Johan Van Hoof, global head of infectious diseases and vaccines at Janssen, said: “Alios BioPharma's pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation.

“This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide.”

The deal is expected to be finalised by the end of the year. 

Article by
Kirstie Pickering

1st October 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...